Recent News

• 04.21.2025 - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
• 03.27.2025 - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
• 03.27.2025 - TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
• 03.25.2025 - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
• 03.25.2025 - TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
• 03.24.2025 - TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 03.24.2025 - TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 03.13.2025 - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
• 03.13.2025 - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
• 02.25.2025 - TransCode Therapeutics, Inc. Announces Results of Special Meeting

Recent Filings

• 04.16.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.15.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.11.2025 - DEF 14A Other definitive proxy statements
• 04.02.2025 - PRE 14A Other preliminary proxy statements
• 03.31.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report
• 03.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.20.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership